Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
Completed · Phase 1 · NCT04883957
Conditions: Mature B-cell Malignancies
At a glance
- Research payments reported, 2025
- $35,650
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 64
About the trial
- Sponsor
- BeiGene
- Tested
- BGB-11417 (drug)
- Dates
- Started 2021-07-05; completion 2026-09-01
- Results posted
- Not yet
The purpose of this study is to evaluate the safety and tolerability of BGB-11417 monotherapy, define the maximum tolerated dose (MTD) or maximum administered dose and the recommended Phase 2 dose (RP2D) of BGB-11417 monotherapy for the selected B-cell malignancy dose finding cohorts, and evaluate the safety and tolerability of the ramp-up dosing schedule in the evaluated disease types.
From ClinicalTrials.gov, last updated 2026-09-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene, Ltd. reported $35,650 in research payments for this study in 2025 (19 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ira Smalberg, MD Radiology · Santa Monica, CA
- George R. Oliveira, M.D. Interventional Radiology · Miami, FL
- Mark A. Anderson, MD Radiology · Boston, MA
- Cheryl A. Sadow, MD Radiology · Boston, MA
- Vikram A. Sahni, M.D. Radiology · Wellesley, MA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ggs Diagnostics LLC $13,090
- Mgpo Radiology Associates $8,820
- Peritus Imaging Inc $7,620
- Radmetrix $5,400
- Vx3 Imaging PC $720
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.